1Whitton ME, Ashcroft DM, Gonzalez U. Therapeutic interventions for vitiligo [J]. J Am Acad Dermatol, 2008, 59(4) : 713-717.
2Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical inci- dent analysis [J]. J Am Acad Dermatol, 1996, 35(6) : 895-898.
3Parsad D, Pandhi R, Dogra S, et al. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome [ J]. Br J Der -matol, 2003, 148(2) : 373-374.
4Lan CC, Chen GS, Chiou MH, et al. FKS06 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migra- tion via keratinocytes: possible mechanisms of how tacrolimus oint- mentinduces repigmentation in patients with vitiligo [J]. BrJ Derma- tol, 2005, 153(3): 498-505.
8Yamanaka KI, Kakeda M, Kitagawa H, et al. 1,24-Dihydroxyvita- min D3(tacalcitol) prevents skin T-cell infiltration [ J ]. Br J Derma- tol, 2010, 162(6) : 1206-1215.
9Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigment- ation [J]. Curr Drug Targets, 2008, 9(4) : 345-359.
10Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo [ J ]. J Eur Acad Dermatol Venereal, 2006, 20(5) : 553-557.
